Maged Shenouda - May 16, 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Financial Officer
Signature
/s/ Maged Shenouda
Stock symbol
RLMD
Transactions as of
May 16, 2025
Transactions value $
$97,208
Form type
4
Date filed
5/20/2025, 06:03 PM
Previous filing
Sep 11, 2024
Next filing
Jun 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shenouda Maged Chief Financial Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES /s/ Maged Shenouda 2025-05-20 0001658369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $22.1K +50K +56.6% $0.44 138K May 16, 2025 Direct F1, F2
transaction RLMD Common Stock Purchase $43.7K +90K +65.06% $0.49 228K May 19, 2025 Direct F1, F3
transaction RLMD Common Stock Purchase $31.4K +60K +26.28% $0.52 288K May 20, 2025 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $0.4229 to $0.4674 per share, inclusive.
F3 Purchase prices range from $0.4493 to $0.4998 per share, inclusive.
F4 Purchase prices range from $0.4998 to $0.5396 per share, inclusive.